Citations (20)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (8)
Carlos Henrique Botelho, Maria Del Pilar Estevez-Diz & Alessandro Gonçalves Campolina. (2022) Cost-effectiveness analysis of trastuzumab for early breast cancer in Brazil. Expert Review of Pharmacoeconomics & Outcomes Research 22:1, pages 63-72.
Read now
Read now
Anne Julienne Genuino, Mac Ardy Junio Gloria, Usa Chaikledkaew, Thanyanan Reungwetwattana & Ammarin Thakkinstian. (2021) Economic evaluation of adjuvant trastuzumab therapy for HER2-positive early-stage breast cancer: systematic review and quality assessment. Expert Review of Pharmacoeconomics & Outcomes Research 21:5, pages 1001-1010.
Read now
Read now
Nour Hisham Al-Ziftawi, Asrul Akmal Shafie & Mohamed Izham Mohamed Ibrahim. (2021) Cost-effectiveness analyses of breast cancer medications use in developing countries: a systematic review. Expert Review of Pharmacoeconomics & Outcomes Research 21:4, pages 655-666.
Read now
Read now
Giorgio Mustacchi. (2021) Cost/benefit evaluations in low-middle/upper-middle income countries: biases about “out of pocket money”. Current Medical Research and Opinion 37:5, pages 819-820.
Read now
Read now
Rita De Santis. (2020) Anti-ErbB2 immunotherapeutics: struggling to make better antibodies for cancer therapy. mAbs 12:1.
Read now
Read now
Der-Yuan Chen, Ping-Ning Hsu, Chao-Hsiun Tang, Lindsay Claxton, Satish Valluri & Robert A. Gerber. (2019) Tofacitinib in the treatment of moderate-to-severe rheumatoid arthritis: a cost-effectiveness analysis compared with adalimumab in Taiwan. Journal of Medical Economics 22:8, pages 777-787.
Read now
Read now
Panagiotis Petrou. (2019) Looking for Her (2+): A systematic review of the economic evaluations of Trastuzumab in early stage HER 2 positive breast cancer. Expert Review of Pharmacoeconomics & Outcomes Research 19:2, pages 115-125.
Read now
Read now
Henry W. C. Leung, Agnes L. F. Chan, Chih-Hsin Muo & John Hang Leung. (2018) Cost-effectiveness of pertuzumab combined with trastuzumab and docetaxel as a first-line treatment for HER-2 positive metastatic breast cancer. Expert Review of Pharmacoeconomics & Outcomes Research 18:2, pages 207-213.
Read now
Read now
Articles from other publishers (12)
Hsiang-Wen Lin, Chen-Yuan Lin, Tzu-Pei Yeh, Tien-Chao Lin, Wan-Chen Yeh, Lin-Chun Yang, Yu-Chieh Chen, Li-Ying Chiu, Chen-Teng Wu, Chih-Jung Chen, Yu-Fen Chen, Hwei-Chung Wang, Yao-Chung Wu & Liang-Chih Liu. (2023) Quality of care in the course of subcutaneous versus intravenous trastuzumab administration in patients with breast cancer: an integrated time–motion study with mixed-methods research. BMJ Open 13:3, pages e059288.
Crossref
Crossref
Takaaki Konishi, Michimasa Fujiogi, Nobuaki Michihata, Hiroyuki Ohbe, Hiroki Matsui, Kiyohide Fushimi, Masahiko Tanabe, Yasuyuki Seto & Hideo Yasunaga. (2022) Cost-effectiveness analysis of trastuzumab monotherapy versus adjuvant chemotherapy plus trastuzumab in elderly patients with HER2-positive early breast cancer. Japanese Journal of Clinical Oncology 52:10, pages 1115-1123.
Crossref
Crossref
Z. Kevin Lu, Xiaomo Xiong, Taiying Lee, Jun Wu, Jing Yuan & Bin Jiang. (2021) Big Data and Real-World Data based Cost-Effectiveness Studies and Decision-making Models: A Systematic Review and Analysis. Frontiers in Pharmacology 12.
Crossref
Crossref
Amanda Pereira-Salgado, Edmond Michael Kwan, Ben Tran, Peter Gibbs, Johann De Bono & Maarten IJzerman. (2021) Systematic Review of Efficacy and Health Economic Implications of Real-world Treatment Sequencing in Prostate Cancer: Where Do the Newer Agents Enzalutamide and Abiraterone Fit in?. European Urology Focus 7:4, pages 752-763.
Crossref
Crossref
Nidhi Gupta, Rohan Kumar Verma, Sudeep Gupta & Shankar Prinja. (2020) Cost Effectiveness of Trastuzumab for Management of Breast Cancer in India. JCO Global Oncology:6, pages 205-216.
Crossref
Crossref
Tsung-Ying Lee, Hsuan-Ying Chen, Tsai-Yun Chen, Sin-Syue Li, Wei-Tse Fang, Yao-Chun Wen, Yu-Wen Lo & Huang-Tz Ou. (2020) Cost-utility analysis of inotuzumab ozogamicin for relapsed or refractory B cell acute lymphoblastic leukemia from the perspective of Taiwan’s health care system. The European Journal of Health Economics 21:7, pages 1105-1116.
Crossref
Crossref
Savvas S. Ioannou, Yiola Marcou, Eleni Kakouri & Michael A. Talias. (2020) Real-World Setting Cost-Effectiveness Analysis Comparing Three Therapeutic Schemes of One-Year Adjuvant Trastuzumab in HER2-Positive Early Breast Cancer from the Cyprus NHS Payer Perspective. International Journal of Environmental Research and Public Health 17:12, pages 4339.
Crossref
Crossref
Zhijia Tang & Weimin Cai. 2020. Pharmacogenomics in Precision Medicine. Pharmacogenomics in Precision Medicine
241
255
.
Noga Gershon, Yakir Berchenko, Peter S. Hall & Daniel A. Goldstein. (2019) Cost effectiveness and affordability of trastuzumab in sub-Saharan Africa for early stage HER2-positive breast cancer. Cost Effectiveness and Resource Allocation 17:1.
Crossref
Crossref
Anne Julienne Genuino, Usa Chaikledkaew, Anna Melissa Guerrero, Thanyanan Reungwetwattana & Ammarin Thakkinstian. (2019) Cost-utility analysis of adjuvant trastuzumab therapy for HER2-positive early-stage breast cancer in the Philippines. BMC Health Services Research 19:1.
Crossref
Crossref
Noor Razilah Abdul Rafar, Yet Hoi Hong, David Bin-Chia Wu, Muhamad Faiz Othman & Chin Fen Neoh. (2019) Cost-Effectiveness of Adjuvant Trastuzumab Therapy for Early Breast Cancer in Asia: A Systematic Review. Value in Health Regional Issues 18, pages 151-158.
Crossref
Crossref
Ronnachai Kongsakon, Surasit Lochid-amnuay, Nattiya Kapol & Oraluck Pattanaprateep. (2019) From Research to Policy Implementation: Trastuzumab in Early-Stage Breast Cancer Treatment in Thailand. Value in Health Regional Issues 18, pages 47-53.
Crossref
Crossref